Cargando…
Single High Intensity Focused Ultrasound Session as a Whole Gland Primary Treatment for Clinically Localized Prostate Cancer: 10-Year Outcomes
Objectives. To assess the treatment outcomes of a single session of whole gland high intensity focused ultrasound (HIFU) for patients with localized prostate cancer (PCa). Methods. Response rates were defined using the Stuttgart and Phoenix criteria. Complications were graded according to the Clavie...
Autores principales: | , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Hindawi Publishing Corporation
2014
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4089848/ https://www.ncbi.nlm.nih.gov/pubmed/25045541 http://dx.doi.org/10.1155/2014/186782 |
_version_ | 1782325187562176512 |
---|---|
author | Limani, Ksenija Aoun, Fouad Holz, Serge Paesmans, Marianne Peltier, Alexandre van Velthoven, Roland |
author_facet | Limani, Ksenija Aoun, Fouad Holz, Serge Paesmans, Marianne Peltier, Alexandre van Velthoven, Roland |
author_sort | Limani, Ksenija |
collection | PubMed |
description | Objectives. To assess the treatment outcomes of a single session of whole gland high intensity focused ultrasound (HIFU) for patients with localized prostate cancer (PCa). Methods. Response rates were defined using the Stuttgart and Phoenix criteria. Complications were graded according to the Clavien score. Results. At a median follow-up of 94months, 48 (44.4%) and 50 (46.3%) patients experienced biochemical recurrence for Phoenix and Stuttgart definition, respectively. The 5- and 10-year actuarial biochemical recurrence free survival rates were 57% and 40%, respectively. The 10-year overall survival rate, cancer specific survival rate, and metastasis free survival rate were 72%, 90%, and 70%, respectively. Preoperative high risk category, Gleason score, preoperative PSA, and postoperative nadir PSA were independent predictors of oncological failure. 24.5% of patients had self-resolving LUTS, 18.2% had urinary tract infection, and 18.2% had acute urinary retention. A grade 3b complication occurred in 27 patients. Pad-free continence rate was 87.9% and the erectile dysfunction rate was 30.8%. Conclusion. Single session HIFU can be alternative therapy for patients with low risk PCa. Patients with intermediate risk should be informed about the need of multiple sessions of HIFU and/or adjuvant treatments and HIFU performed very poorly in high risk patients. |
format | Online Article Text |
id | pubmed-4089848 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2014 |
publisher | Hindawi Publishing Corporation |
record_format | MEDLINE/PubMed |
spelling | pubmed-40898482014-07-20 Single High Intensity Focused Ultrasound Session as a Whole Gland Primary Treatment for Clinically Localized Prostate Cancer: 10-Year Outcomes Limani, Ksenija Aoun, Fouad Holz, Serge Paesmans, Marianne Peltier, Alexandre van Velthoven, Roland Prostate Cancer Clinical Study Objectives. To assess the treatment outcomes of a single session of whole gland high intensity focused ultrasound (HIFU) for patients with localized prostate cancer (PCa). Methods. Response rates were defined using the Stuttgart and Phoenix criteria. Complications were graded according to the Clavien score. Results. At a median follow-up of 94months, 48 (44.4%) and 50 (46.3%) patients experienced biochemical recurrence for Phoenix and Stuttgart definition, respectively. The 5- and 10-year actuarial biochemical recurrence free survival rates were 57% and 40%, respectively. The 10-year overall survival rate, cancer specific survival rate, and metastasis free survival rate were 72%, 90%, and 70%, respectively. Preoperative high risk category, Gleason score, preoperative PSA, and postoperative nadir PSA were independent predictors of oncological failure. 24.5% of patients had self-resolving LUTS, 18.2% had urinary tract infection, and 18.2% had acute urinary retention. A grade 3b complication occurred in 27 patients. Pad-free continence rate was 87.9% and the erectile dysfunction rate was 30.8%. Conclusion. Single session HIFU can be alternative therapy for patients with low risk PCa. Patients with intermediate risk should be informed about the need of multiple sessions of HIFU and/or adjuvant treatments and HIFU performed very poorly in high risk patients. Hindawi Publishing Corporation 2014 2014-06-19 /pmc/articles/PMC4089848/ /pubmed/25045541 http://dx.doi.org/10.1155/2014/186782 Text en Copyright © 2014 Ksenija Limani et al. https://creativecommons.org/licenses/by/3.0/ This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Clinical Study Limani, Ksenija Aoun, Fouad Holz, Serge Paesmans, Marianne Peltier, Alexandre van Velthoven, Roland Single High Intensity Focused Ultrasound Session as a Whole Gland Primary Treatment for Clinically Localized Prostate Cancer: 10-Year Outcomes |
title | Single High Intensity Focused Ultrasound Session as a Whole Gland Primary Treatment for Clinically Localized Prostate Cancer: 10-Year Outcomes |
title_full | Single High Intensity Focused Ultrasound Session as a Whole Gland Primary Treatment for Clinically Localized Prostate Cancer: 10-Year Outcomes |
title_fullStr | Single High Intensity Focused Ultrasound Session as a Whole Gland Primary Treatment for Clinically Localized Prostate Cancer: 10-Year Outcomes |
title_full_unstemmed | Single High Intensity Focused Ultrasound Session as a Whole Gland Primary Treatment for Clinically Localized Prostate Cancer: 10-Year Outcomes |
title_short | Single High Intensity Focused Ultrasound Session as a Whole Gland Primary Treatment for Clinically Localized Prostate Cancer: 10-Year Outcomes |
title_sort | single high intensity focused ultrasound session as a whole gland primary treatment for clinically localized prostate cancer: 10-year outcomes |
topic | Clinical Study |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4089848/ https://www.ncbi.nlm.nih.gov/pubmed/25045541 http://dx.doi.org/10.1155/2014/186782 |
work_keys_str_mv | AT limaniksenija singlehighintensityfocusedultrasoundsessionasawholeglandprimarytreatmentforclinicallylocalizedprostatecancer10yearoutcomes AT aounfouad singlehighintensityfocusedultrasoundsessionasawholeglandprimarytreatmentforclinicallylocalizedprostatecancer10yearoutcomes AT holzserge singlehighintensityfocusedultrasoundsessionasawholeglandprimarytreatmentforclinicallylocalizedprostatecancer10yearoutcomes AT paesmansmarianne singlehighintensityfocusedultrasoundsessionasawholeglandprimarytreatmentforclinicallylocalizedprostatecancer10yearoutcomes AT peltieralexandre singlehighintensityfocusedultrasoundsessionasawholeglandprimarytreatmentforclinicallylocalizedprostatecancer10yearoutcomes AT vanvelthovenroland singlehighintensityfocusedultrasoundsessionasawholeglandprimarytreatmentforclinicallylocalizedprostatecancer10yearoutcomes |